Peer-Reviewed Journal Details
Mandatory Fields
McVeigh, TP,Jung, SY,Kerin, MJ,Salzman, DW,Nallur, S,Nemec, AA,Dookwah, M,Sadofsky, J,Paranjape, T,Kelly, O,Chan, E,Miller, N,Sweeney, KJ,Zelterman, D,Sweasy, J,Pilarski, R,Telesca, D,Slack, FJ,Weidhaas, JB
Cell Cycle
Estrogen withdrawal, increased breast cancer risk and the KRAS-variant
Altmetric: 9WOS: 5 ()
Optional Fields
breast cancer risk estrogen withdrawal KRAS-variant multiple primary breast cancer triple negative breast cancer tumor biology MICRORNA-BINDING-SITE WOMEN EPIDEMIOLOGY POLYMORPHISM MUTATIONS RECEPTOR THERAPY CELLS
The KRAS-variant is a biologically functional, microRNA binding site variant, which predicts increased cancer risk especially for women. Because external exposures, such as chemotherapy, differentially impact the effect of this mutation, we evaluated the association of estrogen exposures, breast cancer (BC) risk and tumor biology in women with the KRAS-variant. Women with BC (n = 1712), the subset with the KRAS-variant (n = 286) and KRAS-variant unaffected controls (n = 80) were evaluated, and hormonal exposures, KRAS-variant status, and pathology were compared. The impact of estrogen withdrawal on transformation of isogenic normal breast cell lines with or without the KRAS-variant was studied. Finally, the association and presentation characteristics of the KRAS-variant and multiple primary breast cancer (MPBC) were evaluated. KRAS-variant BC patients were more likely to have ovarian removal pre-BC diagnosis than non-variant BC patients (p = 0.033). In addition, KRAS-variant BC patients also appeared to have a lower estrogen state than KRAS-variant unaffected controls, with a lower BMI (P < 0.001). Finally, hormone replacement therapy (HRT) discontinuation in KRAS-variant patients was associated with a diagnosis of triple negative BC (P < 0.001). Biologically confirming our clinical findings, acute estrogen withdrawal led to oncogenic transformation in KRAS-variant positive isogenic cell lines. Finally, KRAS-variant BC patients had greater than an 11-fold increased risk of presenting with MPBC compared to non-variant patients (45.39% vs 6.78%, OR 11.44 [3.42-37.87], P < 0.001). Thus, estrogen withdrawal and a low estrogen state appear to increase BC risk and to predict aggressive tumor biology in women with the KRAS-variant, who are also significantly more likely to present with multiple primary breast cancer.
Grant Details
Publication Themes